Getting it Right in Crohn’s Disease: A Clinical Guideline and Decision Tool-Based Approach (part 2 of 2)

Program Overview

Despite evidence supporting usefulness of patient-specific risk stratification and personalized treatment, many patients with Crohn’s disease continue to be undertreated. In this activity, learners will explore new and available tools to help risk stratify patients with Crohn’s disease, predict the likelihood of response to various biologic therapies, and select appropriate treatment using these tools and AGA guidelines and care pathways. This activity provides tool demonstrations, video commentary, and case presentations all in one interactive, self-paced infographic.

Click for Part 1

Credit Expired
0.25 CE Credit(s)
Expires: April 21, 2023

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Faculty


Parambir S. Dulai, MD

Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine Northwestern University
Evanston, IL

Corey Siegel MD

Corey A. Siegel, MD, MS

Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Hanover, NH

Supporter Statement

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Provider Statement

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources